Cargando…

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease

Non-alcoholic fatty liver disease is marked by hepatic fat accumulation not due to alcohol abuse. Several studies have demonstrated that NAFLD is associated with insulin resistance leading to a resistance in the antilipolytic effect of insulin in the adipose tissue with an increase of free fatty aci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaggini, Melania, Morelli, Mariangela, Buzzigoli, Emma, DeFronzo, Ralph A., Bugianesi, Elisabetta, Gastaldelli, Amalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708335/ https://www.ncbi.nlm.nih.gov/pubmed/23666091 http://dx.doi.org/10.3390/nu5051544

Ejemplares similares

Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease
por: Gaggini, Melania, et al.
Publicado: (2019)

Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
por: Salehi, Marzieh, et al.
Publicado: (2022)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

PSUN299 GLP-1 Contribution to Insulin Secretory Response to Protein Ingestion and Insulin Kinetics Following Gastric Bypass and Sleeve Gastrectomy
por: Rayas, Maria, et al.
Publicado: (2022)

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
por: Mehta, Rucha J., et al.
Publicado: (2019)

201 Effects of GLP-1 on Glucose and Islet-Cell Secretory Responses to Protein Ingestion After Gastric Bypass or Sleeve Gastrectomy
por: Rayas, Maria S., et al.
Publicado: (2022)

Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk
por: Carli, Fabrizia, et al.
Publicado: (2023)

Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2022)

The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
por: Saponaro, Chiara, et al.
Publicado: (2015)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
por: Pierantonelli, Irene, et al.
Publicado: (2017)

Author Correction: Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
por: Pierantonelli, Irene, et al.
Publicado: (2017)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2021)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases
por: Wójcik-Cichy, Kamila, et al.
Publicado: (2018)

Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia
por: Gaggini, Melania, et al.
Publicado: (2022)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Atherosclerosis, Dyslipidemia, and Inflammation: The Significant Role of Polyunsaturated Fatty Acids
por: Dessì, Mariarita, et al.
Publicado: (2013)

Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp.
por: Blanco, Cynthia L., et al.
Publicado: (2018)

Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load
por: Gambino, Roberto, et al.
Publicado: (2016)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
por: Luukkonen, Panu K., et al.
Publicado: (2022)

Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Conlon, Beth A., et al.
Publicado: (2013)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Tanase, Daniela Maria, et al.
Publicado: (2021)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

A novel experimental model for human mixed acinar–ductal pancreatic cancer
por: Doiron, Bruno, et al.
Publicado: (2018)

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
por: Akhtar, Daud H., et al.
Publicado: (2019)

Role of Insulin Clearance in Insulin Action and Metabolic Diseases
por: Ghadieh, Hilda E., et al.
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers
por: Sanna, Claudia, et al.
Publicado: (2016)

Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD
por: Mavromati, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5t2di29rj7gqj5aclcg4ppbmbe